Drug Trial Radar · NCT01241591
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Dec 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,101
Actual
Start
Nov 2010
Primary completion
Jan 2013
Study completion Jan 2013
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 16, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
Conditions
- Psoriasis
Interventions
CP 690,550 5 mgDrug
CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
CP 690,550 10 mgDrug
CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
Etanercept 50 mgBiological
Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
PlaceboOther
Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12Time frame: Week 12
- Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12Time frame: Week 12
Locations
122 sites in 26 countries. Site status is shown where the registry gives one.
Centro de Investigaciones Dermatologicas
Buenos Aires, Argentina
IMAI (Instituto Medico de Asistencia e Investigaciones)
Buenos Aires, Argentina
Centro de Investigaciones Dermatologicas
Buenos Aires, C1114aap, Argentina
LKH Feldkirch Abteilung fuer Dermatologie und Venerologie
Feldkirch, Austria
LKH Innsbruck Universitaetsklinik fuer Dermatologie und Venerologie
Innsbruck, Austria
LKH Salzburg, Landesklinik fuer Dermatologie
Salzburg, Austria
Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhuegel
Vienna, Austria
Cliniques universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Department for skin and venerial diseases, Clinical Center University of Sarajevo
Sarajevo, Bosnia and Herzegovina
Universitetska Mnogoprofilna Bolnitsa Za Aktivno Lechenie- Dr Georgi Stranski- Pleven
Pleven, Bulgaria
Tsentar za kozhno-venericheski zaboliavania" EOOD
Sofia, Bulgaria
Mnogoprofilna Bolnitsa Za Aktivno Lechenie- Tokuda Bolnitsa Sofia- Sofia
Sofia, Bulgaria
Universitetska mnogoprofilna bolnitsa za aktivno lechenie- Alexandrovska- Sofia
Sofia, Bulgaria
MBAL na Voennomeditsinska akademia- Sofia
Sofia, Bulgaria
Clinica Dermovein S.A.
Santiago, Chile
Hospital Clinico Universidad de Chile, Departamento Dermatologia
Santiago, Chile
Clinica Davila
Santiago, Rm 8431657, RM, Chile
Centro de Especialidades Dermatologicas
Viña del Mar, Valparaiso, Chile
Reumalab S.A.S.
Medellín, Antioquia, Colombia
Centro Integral de Reumatología del Caribe Circaribe S.A
Barranquilla, Atlántico, Colombia
Centro de Investigacion Clinica de la Universidad del Rosario
Bogota, Cundinamarca, Colombia
Riesgo de Fractura S.A.
Bogota, Cundinamarca, Colombia
Medicity S.A.S
Bucaramanga, Santander Department, Colombia
Department of Dermatovenerology, University Hospital Center Osijek
Osijek, Croatia
Dermatovenerological Clinic, University hospital center "Sestre milosrdnice"
Zagreb, Croatia
Department of dermatovenerology, University Hospital Center Zagreb
Zagreb, Croatia
Nemocnice Ceske Budejovice, a.s.
České Budějovice, Czechia
FN Kradec Kralove
Hradec Králové, Czechia
Fakultni nemocnice Plzen
Plzen - Bory, Czechia
Kozni ordinace
Prague, Czechia
Kralska zdravotni a.s., Masarykovy nemocnice o.z.
Ústí nad Labem, Czechia
Kralska zdravotni
Ústí nad Labem, Czechia
Department of Dermatology, Aarhus University Hospital
Aarhus C, Denmark
Bispebjerg Hospital, University of Copenhagen
Copenhagen NV, Denmark
Hudklinikken Herning
Herning, Denmark
CHU de Besancon - Hopital Saint Jacques
Besançon, France
Hopital Ambroise Pare, Service de Dermatologie
Boulogne, France
Chu Morvan
Brest Cédex, France
Hopital Dupuytren
Limoges, France
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.